BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31:468-475. [PMID: 3009109 DOI: 10.1007/bf01320309] [Cited by in Crossref: 398] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Oikonomou T, Goulis I, Soulaidopoulos S, Karasmani A, Doumtsis P, Tsioni K, Mandala E, Akriviadis E, Cholongitas E. High serum ferritin is associated with worse outcome of patients with decompensated cirrhosis. Ann Gastroenterol. 2017;30:217-224. [PMID: 28243043 DOI: 10.20524/aog.2016.0112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
2 Lo Re V, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011;20:689-699. [PMID: 21626605 DOI: 10.1002/pds.2148] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 9.5] [Reference Citation Analysis]
3 Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver Int 2019;39:127-35. [PMID: 30107095 DOI: 10.1111/liv.13943] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
4 Scheiner B, Stammet PR, Pokorny S, Bucsics T, Schwabl P, Brichta A, Thaler J, Lampichler K, Ba-Ssalamah A, Ay C. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr. 2018;. [PMID: 29916054 DOI: 10.1007/s00508-018-1351-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
5 Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Lo Re V 3rd. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 2014;58:1449-58. [PMID: 24569533 DOI: 10.1093/cid/ciu097] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
6 Jeon JW, Shin HP, Lee JI, Joo KR, Pack KM, Cha JM, Park JJ, Lim JU, Lim K. The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis. Surg Endosc 2012;26:3258-63. [PMID: 22648106 DOI: 10.1007/s00464-012-2334-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
7 Graziotto A, Rossaro L, Inturri P, Salvagnini M. Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Dig Dis Sci. 1997;42:1708-1714. [PMID: 9286238 DOI: 10.1023/a:1018865516168] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
8 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
9 Ingrand P, Gournay J, Bernard P, Oberti F, Bernard-Chabert B, Pauwels A, Renard P, Bartoli E, Cadranel JF, Barbare JC, Ingrand I, Beauchant M, Portale TCFPLL. Management of digestive bleeding related to portal hypertension in cirrhotic patients: A French multicenter cross-sectional practice survey. World J Gastroenterol 2006; 12(48): 7810-7814 [PMID: 17203525 DOI: 10.3748/wjg.v12.i48.7810] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Reardon JM, O'Connor SM, Njau JD, Lam EK, Staton CA, Cookson ST. Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies. Confl Health 2019;13:5. [PMID: 30858875 DOI: 10.1186/s13031-019-0188-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS One 2019;14:e0221614. [PMID: 31449554 DOI: 10.1371/journal.pone.0221614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nasr G, Hassan A, Ahmed S, Serwah A. Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res 2010;1:136-44. [PMID: 21187868 DOI: 10.4103/0975-3583.70914] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
13 Cortez-Pinto H, Baptista A, Camilo ME, De Moura MC. Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 2003;48:1909-1913. [PMID: 14627331 DOI: 10.1023/a:1026152415917] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
14 Gluud LL, Jeyaraj R, Morgan MY. Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:354-61. [PMID: 31360028 DOI: 10.1016/j.jceh.2019.02.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R, Rendon G; Portal Hypertension Collaborative Group. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009;7:689-695. [PMID: 19281860 DOI: 10.1016/j.cgh.2009.02.021] [Cited by in Crossref: 136] [Cited by in F6Publishing: 121] [Article Influence: 11.3] [Reference Citation Analysis]
16 Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World J Hepatol 2015; 7(13): 1797-1806 [PMID: 26167253 DOI: 10.4254/wjh.v7.i13.1797] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
17 Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55 Suppl 6:vi1-v12. [PMID: 16966752 DOI: 10.1136/gut.2006.099580] [Cited by in Crossref: 153] [Cited by in F6Publishing: 149] [Article Influence: 10.9] [Reference Citation Analysis]
18 Ibrahim M, El-Mikkawy A, Abdel Hamid M, Abdalla H, Lemmers A, Mostafa I, Devière J. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut 2019;68:844-53. [PMID: 29730601 DOI: 10.1136/gutjnl-2017-314653] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
19 Wang X, Xie G, Wang X, Zhou M, Yu H, Lin Y, Du G, Luo G, Liu P. Urinary metabolite profiling offers potential for differentiation of liver-kidney yin deficiency and dampness-heat internal smoldering syndromes in posthepatitis B cirrhosis patients. Evid Based Complement Alternat Med 2015;2015:464969. [PMID: 25667596 DOI: 10.1155/2015/464969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
20 Phillip V, Saugel B, Ernesti C, Hapfelmeier A, Schultheiß C, Thies P, Mayr U, Schmid RM, Huber W. Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. BMC Gastroenterol. 2014;14:18. [PMID: 24467993 DOI: 10.1186/1471-230X-14-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
21 Romanelli RG, Villa GL, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. World J Gastroenterol 2006; 12(9): 1403-1407 [PMID: 16552809 DOI: 10.3748/wjg.v12.i9.1403] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
22 Patel A, Asch S, Antonio AL, Kanwal F, Lorenz K, Riopelle D, Dickey A, Larkin J, Lee M, Walling A. Measuring the Quality of Palliative Care for Patients with End-Stage Liver Disease. Dig Dis Sci 2020;65:2562-70. [PMID: 31927765 DOI: 10.1007/s10620-019-05983-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Amodio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, Minazzato L. Hepatitis C virus infection and health-related quality of life. World J Gastroenterol 2012; 18(19): 2295-2299 [PMID: 22654420 DOI: 10.3748/wjg.v18.i19.2295] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
24 Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Goto T, Yoshida H, Kanai F, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M. Comparison of liver biopsy and transient elastography based on clinical relevance. Can J Gastroenterol 2008;22:753-7. [PMID: 18818788 DOI: 10.1155/2008/306726] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
25 Sturm L, Bettinger D, Giesler M, Boettler T, Schmidt A, Buettner N, Thimme R, Schultheiss M. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United European Gastroenterol J 2018;6:1380-90. [PMID: 30386611 DOI: 10.1177/2050640618795928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
26 Wallerstedt S, Simrén M, Wahlin S, Lööf L, Hultcrantz R, Sjöberg K, Gertzén HS, Prytz H, Almer S, Odén A. Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. Scand J Gastroenterol 2013;48:358-65. [PMID: 23298384 DOI: 10.3109/00365521.2012.743583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
27 Vatsalya V, Liaquat HB, Ghosh K, Mokshagundam SP, McClain CJ. A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking. Curr Drug Abuse Rev 2016;9:87-92. [PMID: 28124600 DOI: 10.2174/1874473710666170125151410] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
28 Maruyama H, Kondo T, Sekimoto T, Yokosuka O. Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension. Medicine (Baltimore) 2015;94:e1056. [PMID: 26131820 DOI: 10.1097/MD.0000000000001056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
29 Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017;5:138-147. [PMID: 28533911 DOI: 10.1093/gastro/gox013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
30 Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Ann Surg. 1999;229:84-90. [PMID: 9923804 DOI: 10.1097/00000658-199901000-00011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 3.5] [Reference Citation Analysis]
31 Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform 2019;3:1-12. [PMID: 30892921 DOI: 10.1200/CCI.18.00097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
32 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 117] [Article Influence: 10.7] [Reference Citation Analysis]
33 Ripoll C, Bari K, Garcia-Tsao G. Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis. J Clin Gastroenterol 2015;49:613-9. [PMID: 25203362 DOI: 10.1097/MCG.0000000000000207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
34 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
35 Aamann L, Dam G, Rinnov AR, Vilstrup H, Gluud LL. Physical exercise for people with cirrhosis. Cochrane Database Syst Rev 2018;12:CD012678. [PMID: 30575956 DOI: 10.1002/14651858.CD012678.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 21.6] [Reference Citation Analysis]
37 Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. Int J Hepatol. 2012;2012:318627. [PMID: 22811919 DOI: 10.1155/2012/318627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
38 Kruger AJ, Mumtaz K, Anaizi A, Modi RM, Hussan H, Zhang C, Hinton A, Conwell DL, Krishna SG, Stanich PP. Cirrhosis Is Associated with Increased Mortality in Patients with Diverticulitis: A Nationwide Cross-Sectional Study. Dig Dis Sci 2017;62:3149-55. [PMID: 28986716 DOI: 10.1007/s10620-017-4782-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
39 Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V. Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr. 2009;121:732-744. [PMID: 20047110 DOI: 10.1007/s00508-009-1288-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
40 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
41 D'Amico G, Malizia G, D'Amico M. Prognosis research and risk of bias. Intern Emerg Med 2016;11:251-60. [PMID: 26910239 DOI: 10.1007/s11739-016-1404-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
42 Simonetti RG, Cammà C, Fiorello F, Politi F, D’Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36:962-972. [PMID: 1649041 DOI: 10.1007/bf01297149] [Cited by in Crossref: 240] [Cited by in F6Publishing: 93] [Article Influence: 8.0] [Reference Citation Analysis]
43 Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396-405. [PMID: 21520194 DOI: 10.1002/hep.24370.24370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Huang YF, Lin CS, Cherng YG, Yeh CC, Chen RJ, Chen TL, Liao CC. A population-based cohort study of mortality of intensive care unit patients with liver cirrhosis. BMC Gastroenterol 2020;20:15. [PMID: 31948392 DOI: 10.1186/s12876-020-1163-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar WA, Fontanet A, Mohamed MK, Yazdanpanah Y. Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Med Res Methodol 2014;14:39. [PMID: 24635942 DOI: 10.1186/1471-2288-14-39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
46 Corrao G, Torchio P, Zambon A, Ferrari P, Aricò S, di Orio F. Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus infections on the risk of symptomatic liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Eur J Epidemiol. 1998;14:447-456. [PMID: 9744676 DOI: 10.1023/a:1007411423766] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
47 Violi F, Alessandri C, Ferro D, Saliola M, Cordova C, Musca A, Balsano F. Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis. J Clin Pathol 1989;42:1246-9. [PMID: 2613916 DOI: 10.1136/jcp.42.12.1246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
48 Propst A, Propst T, Zangerl G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci. 1995;40:1805-1815. [PMID: 7648984 DOI: 10.1007/bf02212706] [Cited by in Crossref: 79] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
49 Konopke R, Kersting S, Bunk A, Dietrich J, Denz A, Gastmeier J, Saeger H. Colorectal liver metastasis surgery: analysis of risk factors predicting postoperative complications in relation to the extent of resection. Int J Colorectal Dis 2009;24:687-97. [DOI: 10.1007/s00384-009-0669-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
50 Parkash O, Iqbal R, Jafri F, Azam I, Jafri W. Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes. 2012;5:446. [PMID: 22905795 DOI: 10.1186/1556-0500.5.446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR 2013;1:62-82. [DOI: 10.36469/9854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008;35:25-32. [PMID: 18541174 DOI: 10.1016/j.amepre.2008.03.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
53 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;CD003044. [PMID: 27153247 DOI: 10.1002/14651858.cd003044.pub4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
54 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;7:CD002798. [PMID: 28745801 DOI: 10.1002/14651858.CD002798.pub3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Papatheodoridis GV, Cholongitas E, Dimitriadou E, Touloumi G, Sevastianos V, Archimandritis AJ. MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World J Gastroenterol 2005; 11(20): 3099-3104 [PMID: 15918197 DOI: 10.3748/wjg.v11.i20.3099] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
56 Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites. Curr Gastroenterol Rep. 2003;5:240-246. [PMID: 12734047 DOI: 10.1007/s11894-003-0026-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
57 Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-749. [PMID: 15082595 DOI: 10.1136/gut.2003.020263] [Cited by in Crossref: 315] [Cited by in F6Publishing: 277] [Article Influence: 18.5] [Reference Citation Analysis]
58 Ratib S, Fleming KM, Crooks CJ, Walker AJ, West J. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol. 2015;110:1149-1158. [PMID: 26169512 DOI: 10.1038/ajg.2015.191] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
59 Seitz HK, Neuman MG. The History of Alcoholic Liver Disease: From an Unrecognized Disease to One of the Most Frequent Diseases in Hepatology. J Clin Med 2021;10:858. [PMID: 33669694 DOI: 10.3390/jcm10040858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Corrao G, Zambon A, Bagnardi V, Aricò S, Loguercio C, D'Amicis A; Collaborative SIDECIR Group. Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: an explorative case-control study. Eur J Epidemiol 2004;19:861-9. [PMID: 15499896 DOI: 10.1023/b:ejep.0000040534.89451.d2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
61 Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
62 Parkash O, Iqbal R, Jafri F, Azam I, Jafri W. Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes 2012;5:446. [PMID: 22905795 DOI: 10.1186/1756-0500-5-446] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
63 Amodio P. The liver, the brain and nitrogen metabolism. Metab Brain Dis. 2009;24:1-4. [PMID: 19107584 DOI: 10.1007/s11011-008-9120-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Song J, Sun H, Jing J, Carlos L, Chao L, Cash SS, Zhang R, Westover MB. A Mean Field Model of Acute Hepatic Encephalopathy. Annu Int Conf IEEE Eng Med Biol Soc 2018;2018:2366-9. [PMID: 30440882 DOI: 10.1109/EMBC.2018.8512786] [Reference Citation Analysis]
65 Trieu H, Patel A, Wells C, Saab S, Lee EW. Disparities in Mortality and Health Care Utilization for 460,851 Hospitalized Patients with Cirrhosis and Hepatic Encephalopathy. Dig Dis Sci 2021;66:2595-602. [PMID: 32926262 DOI: 10.1007/s10620-020-06582-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Song JL, Paixao L, Li Q, Li SH, Zhang R, Westover MB. A novel neural computational model of generalized periodic discharges in acute hepatic encephalopathy. J Comput Neurosci 2019;47:109-24. [PMID: 31506807 DOI: 10.1007/s10827-019-00727-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
67 Kerbert AJC, Jalan R. Recent advances in understanding and managing hepatic encephalopathy in chronic liver disease. F1000Res 2020;9:F1000 Faculty Rev-312. [PMID: 32399191 DOI: 10.12688/f1000research.22183.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
68 Alali J, Ramji A, Ho JK, Scudamore CH, Erb SR, Cheung E, Kopit B, Bannon CA, Chung SW, Soos JG, Buczkowski AK, Brooks EM, Steinbrecher UP, Yoshida EM. Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol. 2006;20:95-99. [PMID: 16482235 DOI: 10.1155/2006/879103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
69 Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32:1407-1414. [PMID: 22679906 DOI: 10.1111/j.1478-3231.2012.02830.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 104] [Article Influence: 15.3] [Reference Citation Analysis]
70 Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, Kim WR. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018;68:78-88. [PMID: 29023828 DOI: 10.1002/hep.29594] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
71 Sharma P, Sarin SK. Improved survival with the patients with variceal bleed. Int J Hepatol. 2011;2011:356919. [PMID: 21994853 DOI: 10.4061/2011/356919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
72 Muhie OA. Causes and Clinical Profiles of Ascites at University of Gondar Hospital, Northwest Ethiopia: Institution-Based Cross-Sectional Study. Can J Gastroenterol Hepatol 2019;2019:5958032. [PMID: 31360695 DOI: 10.1155/2019/5958032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Al-Busafi SA, McNabb-Baltar J, Farag A, Hilzenrat N. Clinical manifestations of portal hypertension. Int J Hepatol. 2012;2012:203794. [PMID: 23024865 DOI: 10.1155/2012/203794] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
74 Mangtani P, Hall AJ, Normand CE. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health 1995;49:238-44. [PMID: 7629457 DOI: 10.1136/jech.49.3.238] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
75 Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi JM. Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther. 2009;30:741-748. [PMID: 19604177 DOI: 10.1111/j.1365-2036.2009.04096.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
76 El-Bokl MA, Senousy BE, El-Karmouty KZ, Mohammed IEK, Mohammed SM, Shabana SS, Shalaby H. Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites. World J Gastroenterol 2009; 15(29): 3631-3635 [PMID: 19653340 DOI: 10.3748/wjg.15.3631] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
77 Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev 2019;6:CD004039. [PMID: 31251387 DOI: 10.1002/14651858.CD004039.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
78 Merkel C, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, Marchesini G, Ruol A. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci. 1991;36:1197-1203. [PMID: 1893804 DOI: 10.1007/bf01307508] [Cited by in Crossref: 59] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
79 Shetty S, Nagaraju SP, Shenoy S, Attur RP, Rangaswamy D, Rao IR, Mateti UV, Parthasarathy R. Acute kidney injury in patients with cirrhosis of liver: Clinical profile and predictors of outcome. Indian J Gastroenterol 2018;37:248-54. [PMID: 30014435 DOI: 10.1007/s12664-018-0867-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Garcia N, Sanyal AJ. Ascites. Curr Treat Options Gastroenterol. 2001;4:527-537. [PMID: 11696279 DOI: 10.1007/s11938-001-0018-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
81 Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405. [PMID: 21520194 DOI: 10.1002/hep.24370] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
82 Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care. 2012;16:R227. [PMID: 23186071 DOI: 10.1186/cc11882] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 8.2] [Reference Citation Analysis]
83 Patel MV, Patel KB, Gupta S, Michalsen A, Stapelfeldt E, Kessler CS. A Complex Multiherbal Regimen Based on Ayurveda Medicine for the Management of Hepatic Cirrhosis Complicated by Ascites: Nonrandomized, Uncontrolled, Single Group, Open-Label Observational Clinical Study. Evid Based Complement Alternat Med 2015;2015:613182. [PMID: 26339267 DOI: 10.1155/2015/613182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
84 Ney M, Gramlich L, Mathiesen V, Bailey RJ, Haykowsky M, Ma M, Abraldes JG, Tandon P. Patient-perceived barriers to lifestyle interventions in cirrhosis. Saudi J Gastroenterol 2017;23:97-104. [PMID: 28361840 DOI: 10.4103/1319-3767.203357] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
85 Benmassaoud A, Nitulescu R, Pembroke T, Halme AS, Ghali P, Deschenes M, Wong P, Klein MB, Sebastiani G. Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. Clin Infect Dis 2019;69:1422-30. [PMID: 30561558 DOI: 10.1093/cid/ciy1082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]